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SHORT REPORT
Mutation screening in Bo¨rjeson-Forssman-Lehmann
syndrome: identification of a novel de novo PHF6
mutation in a female patient
J Crawford, K M Lower, R C M Hennekam, H Van Esch, A Me´garbane´, S A Lynch,
G Turner, J Ge´cz
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Background: Bo¨rjeson-Forssman-Lehmann syndrome (BFLS;
MIM 301900) is an infrequently described X linked disorder
caused by mutations in PHF6, a novel zinc finger gene of
unknown function.
Objective: To present the results of mutation screening in
individuals referred for PHF6 testing and discuss the value of
prior X-inactivation testing in the mothers of these indivi-
duals.
Results: 25 unrelated individuals were screened (24 male,
one female). Five PHF6 mutations were detected, two of
which (c.940ARG and c.27_28insA) were novel. One of
these new mutations, c.27_28insA, was identified in a female
BFLS patient. This was shown to be a de novo mutation
arising on the paternal chromosome. This is the first report of
a clinically diagnosed BFLS female with a confirmed PHF6
mutation. In addition, the X-inactivation status of the mothers
of 19 males with suggested clinical diagnosis of BFLS was
determined. Skewed (>70%) X-inactivation was present in
five mothers, three of whom had sons in whom a PHF6
mutation was detected. The mutation positive female also
showed skewing.
Conclusions: The results indicate that the success of PHF6
screening in males suspected of having BFLS is markedly
increased if there is a positive family history and/or skewed
X-inactivation is found in the mother.
B
o¨rjeson-Forssman-Lehmann syndrome was first
described in 1962 in a family with severe intellectual
disability, characteristic craniofacial features, microce-
phaly, hypogonadism, obesity, short stature, and epilepsy.1
Identification of the BFLS gene, PHF6,2 has enabled the
causative mutation in this original family to be determined.3
A recent clinical review of 25 affected males from nine
unrelated families with PHF6 mutations showed that the
phenotype is seldom as severe as that seen in the original
patients. Clinical manifestations are quite variable, with the
most consistent features being initial hypotonia, mild to
moderate intellectual disability, large fleshy ears, under-
developed genitalia, gynaecomastia, truncal obesity, tapering
fingers, and shortening of the fourth and fifth toes.4
Heterozygote females may have a milder similar clinical
phenotype, which can include hypothyroidism; however,
many carrier females appear unaffected. Our initial research
indicated that the majority of females carrying known PHF6
mutations show highly skewed X-inactivation in their blood
leucocytes.2 Plenge et al5 analysed X-inactivation skewing in
female carriers from 24 families segregating 20 distinct
X linked mental retardation (XLMR) disorders. They found
that approximately 50% of XLMR carriers showed markedly
(>80%) skewed patterns of X-inactivation, compared with
approximately 10% of the control population. In several
instances where obligate carriers were found to have
pronounced skewing, the pattern of skewing was consistent
throughout the family. Screening of PHF6 in individuals with
a suggested clinical diagnosis of BFLS immediately following
characterisation of the gene identified mutations in all seven
of a group of familial BFLS cases, but in only two of 13
sporadic cases.2 Based on our initial observation of frequently
and consistently skewed X-inactivation in PHF6 mutation
carriers,2 we investigated the use of X-inactivation screening
in the mothers of males with a suggested clinical diagnosis of
BFLS as an indicator of their PHF6 mutation carrier status.
Here we outline our experience with PHF6 mutation screen-
ing, supply a brief family history of the previously unreported
BFLS patients identified in this study, and compile all
currently reported PHF6 mutations.
METHODS
Patients
Since publication of the BFLS gene PHF6,2 25 patients with
clinical features suggestive of BFLS have been referred for
mutation testing to our laboratory. Photographs and detailed
clinical history of the five patients found to have a PHF6
mutation were obtained from the referring clinicians before
mutation detection. A brief family history of the three
unpublished patients is outlined in the results section of this
paper. Patient consent and ethics approval were obtained
locally by the referring clinician for all cases.
X-inactivation studies
X chromosome inactivation status was studied in DNA
extracted from white blood cells from the mothers of boys
with a suggested clinical diagnosis of BFLS, and in the single
girl clinically diagnosed as having BFLS (QIAamp DNA blood
maxi kit, Qiagen Inc, Valencia, California, USA). The X-
inactivation analysis was undertaken using three polymerase
chain reaction (PCR) based assays: HpaII digestion of DNA
followed either by amplification of the androgen receptor
(AR) gene polymorphic CAG repeat,6 or of the FMR1 gene
variable CGG repeat,7 or amplification of the phosphoglyce-
rate kinase-1 (PGK-1) gene followed by digestion of the
polymorphic BstXI site.8 PGK-1 analysis was carried out only
when the patient was uninformative at both AR and FRAXA
loci. Initial analysis of AR and FMR1 repeat regions involved
incorporation of radioactive 32P into each amplicon and
electrophoresis of resultant labelled products on denaturing
Abbreviations: AR, androgen receptor; BFLS, Bo¨rjeson-Forssman-
Lehmann syndrome; ORF, open reading frame; XLMR, X linked mental
retardation
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5% acrylamide gels. We have also used AR and FMR1
amplification with fluorescently labelled primers (FAM and
HEX, respectively) with subsequent analysis of labelled
amplicons on a 3100-Avant genetic analyser (Applied
Biosystems, Foster City, California, USA). The percentage of
skewed X-inactivation in the original cell population from
which the genomic DNA was derived was then determined by
comparison of peak areas in digested versus undigested
samples.9 Digestion conditions, primer sequences, and PCR
conditions are available on request.
PHF6 mutation screening
Mutation screening was undertaken on either the genomic
DNA or EBV transformed lymphoblast cell line RNA of the
individuals with a suggested clinical diagnosis of BFLS.
Genomic DNA was isolated from patient’s white blood cells
using the QIAamp DNA blood maxi kit (Qiagen). Screening
was undertaken on exons 2 to 10, a region that encompasses
the entire PHF6 coding region. Primers were designed in
intronic sequences such that coding sequences and a
minimum of 20 base pairs (bp) of flanking intronic sequence
could be analysed by direct sequencing (table 1). Cycling
conditions for exons 2, 3, 5, 7, and 8 were as follows: 10
cycles of 94 C˚ for 30 seconds, 60 C˚ for 30 seconds, and 72 C˚
for 30 seconds, followed by 25 cycles of 94 C˚ for 30 seconds,
55 C˚ for 30 seconds, and 72 C˚ for 30 seconds. Exons 4, 6, 9,
and 10 were amplified with 94 C˚ for 30 seconds, 55 C˚ for 30
seconds, and 72 C˚ for 30 seconds for 35 cycles. Final
extension for all PHF6 genomic PCRs was 72 C˚ for seven
minutes. Total RNA was isolated, when available, from
patient lymphoblast cell lines with the RNeasy mini kit
(Qiagen); 1 mg of total RNA was oligo-dT reverse transcribed
using SuperScript II RNAse H- reverse transcriptase (Gibco
BRL, Gaithersburg, Maryland, USA) following the manufac-
turer’s instructions. The PHF6 open reading frame (ORF) was
Table 1 PHF6 specific primers used for polymerase chain reaction amplification and
direct sequencing
Primer name Sequence (59 to 39)
Size
(bp) Product (bp)
PHF6ex1-F GTA TCA ACG CTC TGT GGG TC 20 273
PHF6ex1-R GGC CAC CGC CAT CCT CC 17
PHF6ex2-F AAA ATT AAC ATT GTC GCC CTT C 22 287
PHF6ex2-R GAA CAT TCA TGT GTT ATT AAG AG 23
PHF6ex3-F GCC ATT TTT ACT AGA AAA TTA CC 23 235
PHF6ex3-R TTC TCA AGA GGC AGA AAT ACC 21
PHF6ex4-F TTT TCA ATA ACC AAT TTG TTT TCC 24 310
PHF6ex4-R TTT TTA CAA AAG CCC AAA GAA AG 23
PHF6ex5-F TTG GGT GAA GTG TAC TGC TC 20 245
PHF6ex5-R GAA TGT TGA GAT ATG TCT TAT GG 23
PHF6ex6-F AAC TAA TAC TTA TTT TGA GAT TGG 24 314
PHF6ex6-R CAT TTC AAA TGA TGA ACT TTA CC 23
PHF6ex7-F ATG TTA AGT AAG CTT GAA ATA CC 23 250
PHF6ex7-R CAA AAT TGG GCT TAA AAG AAC C 22
PHF6ex8-F CAT TTA ATG TTT CTC TCA TAA GG 23 265
PHF6ex8-R ACT TTA AAT TTT CTG ATG ACT GG 23
PHF6ex9-F TCT TTT TCA ATA GAA AAT AGC TG 23 276
PHF6ex9-R TAA ACT AAT GTC ATC TAT TTA AGG 24
PHF6ex10-F CAT CCA CTA ATG TTG GCA GG 20 261
PHF6ex10-R ATA TAT CAG TGT GTA TTG TAT CC 23
PHF6polyA-F TTT TGT TCT AAC AGA CAT TTA GG 23 285
PHF6polyA-R AAA GCA AGA CTA AAA GGA ACA C 22
PHF6cDNAa-F CAT TTC TTG AGA CTT AAA GTG G 22 605
PHF6cDNAa-R GTT CCA TGG GAG GAT GTG G 19
PHF6cDNAb-F AAC TGG AGC CCT CAT CAC C 19 756/1086*
PHF6cDNAb-R GGC AGT AAA AAG TTA CAA ACC C 22
*Product sizes differ depending on the alternative splicing of intron between exons 10 and 11 (330 bp).
bp, base pair.
16 no
mutation
16 isolated
2 no
mutation
1
mutation
2 no
mutation
3 familial3 isolated
1
mutation
2
mutations
2 familial
5 screened
5 mothers with
skewed X-inactivation
19 screened
19 mothers not skewed,
uninformative, or no DNA
available
24 males
Figure 1 Schematic representation of our experience with screening of
the PHF6 gene in patients clinically diagnosed with Bo¨rjeson-Forssman-
Lehmann syndrome.
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amplified in two PCR products with PHF6-cDNA specific
primers (table 1), under the following cycling conditions:
initial denaturation at 94 C˚ for two minutes, followed by 35
cycles of 94 C˚ for 30 seconds, 56 C˚ for 30 seconds, and 72 C˚
for one +minute. All amplifications were carried out on
100 ng of genomic DNA or 40 ng of cDNA, in a total PCR
volume of 50 ml. PCR products were column purified
(QIAquick PCR purification kit, Qiagen) and one or both
strands were directly sequenced using Big Dye Terminator
v3.0 or v3.1 sequencing chemistry (PE Applied Biosystems).
The following GenBank reference sequences were used: for
PHF6 cDNA, NM_032335; for PHF6 protein, NM_032335; and
for PHF6 genomic DNA, AL591668.
RESULTS
X-inactivation analysis of PHF6 mutation carrier
females
We had access to DNA from 19 mothers of the 25 clinically
referred BFLS patients. We have identified five mothers with
skewed (.70%) X-inactivation, three of whom have sons with
PHF6 mutations. In addition, we tested for, and found, highly
(.90%) skewed X-inactivation in the only one BFLS diag-
nosed female. This pick up rate differs significantly from that
seen for isolated males with a suggested clinical diagnosis of
BFLS for whom the mother’s X-inactivation status was
unknown, uninformative, or not skewed. In the 16 such cases
screened, we failed to detect any PHF6 mutation (fig 1).
Mutation analysis in PHF6
We have conducted mutation screening in a cohort of 25
unrelated individuals clinically suspected of having Bo¨rjeson-
Forssman-Lehmann syndrome. Screening of the PHF6 ORF
has identified mutations in five of these individuals, four
male and one female. Two of the males had the recurrent
p.R342X mutation and are published elsewhere.3 A brief
clinical history of the other two males and the female BFLS
patient is outlined below. The c.2TRC/p.M1T mutation seen
in case 2 has been identified in a previously reported family.2
Both the c.940ARG/p.I314V and c.27_28insA/p.G10fsX21
mutations, identified in cases 1 and 3 respectively, are
unique to this study. The c.940ARG mutation (case 1) results
in a replacement of isoleucine for valine at position p.314.
This isoleucine is 100% conserved among man, orang-utan,
cow, chicken, rat, mouse, xenopus, pufferfish, and zebrafish
(data not shown). Photographs of the BFLS female patient
(case 3) are presented in fig 2A, reproduced with permission.
Mutation identification in this individual is outlined in fig 2B
and described in further detail below. Family history appears
to be a strong indicator of subsequent PHF6 mutation
detection, with mutations identified in three of the five
familial cases studied (fig 1). There were no PHF6 nucleotide
changes detected in the other 20 patients screened and none
of the mutations identified in this study was seen on at least
50 control chromosomes.
Identification of a novel PHF6 mutation in a female
BFLS patient
Case 3 was unique in that the BFLS presenting proband was
female (fig 2A). We first assessed the X-inactivation of this
patient. Upon finding highly (93%) skewed X-inactivation,
we screened her PHF6 locus on genomic DNA. Exonic
sequencing revealed a single nucleotide insertion in exon 2
(c.27_28insA, fig 2b), presumably leading to a subsequent
frameshift and addition of 21 novel amino acids to the PHF6
protein (p.G10fsX21). This mutation, which apparently
results in a premature stop codon in exon 2, was the only
sequence variant detected in the PHF6 open reading frame.
Sequencing of DNA from the proband’s parents showed that
the c.27_28insA mutation arose de novo, as it was not present
in either parent. X-inactivation analysis indicated that the
proband had the maternal chromosome active in 93% of
peripheral blood cells (data not shown). The mother of the
proband also had skewed X-inactivation (28:72). To deter-
mine the parental chromosome on which the c.27_28insA
arose, we have taken advantage of an intronic SNP (intron 2,
IVS2+203G/A) in close distance from the exon 2, where the
c.27_28insA mutation lies. While the paternal chromosome
had allele G at position IVS2+203 and the maternal
chromosomes were both IVS2+203A, the proband is a
IVS+203G/A heterozygote. Subcloning and subsequent
sequencing of genomic PCR products across exon 2, intron
2, and exon 3 (primers PHF6ex2-F and PHF6ex3-R, 597 bp
product) showed that the c.27_28insA mutation was on the
chromosome with the IVS2+203G allele—that is, on the
paternal chromosome (results not shown).
Brief family history of newly identified BFLS patients
Case 1 (c.940ARG/p.I314V)
The proband was born after 42 weeks with a birth weight of
3750 g. Psychomotor developmental delay was recognised
early; he did not walk until two years three months and did
not begin to talk until four years. He has an IQ of 61 and has
major behavioural problems, one of the most pronounced
being lack of any inhibition in sexual contacts. At 18 years he
was 171.5 cm tall with a head circumference of 55.7 cm,
moderate obesity, and marked gynaecomastia. External
Figure 2 Female patient with Bo¨rjeson-Forssman-Lehmann syndrome and an identified PHF6 mutation (case 3). (A) Two photographs of the patient, a
side profile showing a shallow forehead, large ears, and fleshy ear lobes, and a frontal photograph showing a shallow forehead, deep set eyes, and
prominent supraorbital ridges. (B) Sequencing traces illustrating reverse sequencing reactions of PHF6 exon 2 product of case 3 together with a control
normal male trace; n, normal allele; m, mutant allele with the single nucleotide insertion, c.27_28insA; the arrow indicates the position of insertion of
‘‘A’’ where the sequences of the n and m alleles start to differ; arrowheads indicate the orientation of the sequencing reaction; the filled circle indicates
the proband, the empty square a control male. The written permission of the patient’s parents was obtained for reproducing the photographs in panel
A.
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genitalia showed normal post-pubertal development for age.
His limbs showed hypermobility with Y-shaped cutaneous
syndactyly on both feet. The X-inactivation testing on the
mother of the proband showed a 100% skewed X-inactivation
pattern.
Case2 (c.2TRC/p.M1T)
The proband from this family was born at term after
an uneventful pregnancy. His early milestones were
delayed; he walked at four years and began saying a few
words at five years. At approximately 15 years his height
was 140 cm (,3rd centile), weight was 45 kg (5th centile),
and occipito-frontal head circumference (OFC), 53.3 cm
(10th–25th centile). On physical examination there was a
proportionate short stature, triangular face, hyperplastic
supraorbital ridges, deep set eyes, large ears, gynae-
comastia, and lower abdominal obesity. External genital
examination revealed a small penis and small testes with no
evidence of pubertal change. The X-inactivation testing on
the mother of the proband showed random pattern of X-
inactivation.
Case 3 (c.27_28insA/p.G10fsX21)
This proband is a girl who presented with BFLS-like
symptoms. The pregnancy was uneventful. Her birth
weight was 3972 g. She never crawled but she walked at
one year. However, her coordination was poor and she
fell several times. Her speech was delayed and she attended a
speech therapist at three years. She had words at 12–15
months, but these were indistinct. She had a full psycho-
metric test (WPPSI-R) aged four years eight months and her
overall IQ was scored at 84 (verbal scale IQ, 87; performance
IQ, 84). Her thyroid function was detected as abnormal at
seven to eight years; she has had a high level of thyroid
stimulating hormone with a low thyroxine (T4). Her S-
thyroglobulin antibodies were weakly positive (385; normal
range 0 to 325). At 14 years the patient is 180 cm tall (.98th
centile) and weighs 115 kg (.98.6th centile). She has an
OFC of 62 cm (.97th centile) with a remarkably shallow
forehead. She has fleshy earlobes, deep set eyes with a wide
neck and face (see fig 2a). She has broad feet and hammer
toes. At the time of examination (14 years) it was noted she
had auxiliary and pubic hair but had not yet begun
menstruation. She is tactile defensive and emotionally
labile, has poor spatial awareness and startles easily to
noise. Testing of her blood DNA showed a 93% skewed X-
inactivation pattern.
PHF6 mutation summary
Amalgamating the results of our study with those published
by others gives a total of 12 familial and five sporadic cases of
BFLS recognised so far with the identified PHF6 gene
mutation.2 3 10 11 There are currently 12 different PHF6
mutations identified from 17 unrelated BFLS families, with
four of these mutations (c.2TRC; c.134GRA, c.769ARG, and
c.1024CRT) being recurrent (fig 3). Missense mutations are
the most frequent ones, found in 10 of the 17 cases.
Interestingly, PHF6 mutations are not clustered and they do
not seem to predominantly affect the only two recognised
functional domains of the protein, the PHD-like zinc fingers.
In fact just the opposite is seen, with the majority of
mutations found outside the PHD finger regions. These
observations, along with the lack of notable genotype-
phenotype correlations, lead us to propose that the majority,
if not all, PHF6 mutations might cause loss of function of the
PHF6 protein.
DISCUSSION
Since the identification of the causative gene for BFLS in
2002,2 we have analysed 25 clinically diagnosed cases
received from colleagues worldwide (fig 1). Given the size
of the gene (10 exons) we preferentially screened affected
individuals on cDNA generated from lymphoblast cell line
(LCL) RNA; however, as LCLs were not available for every
patient, we also undertook screening on genomic DNA
(supplementary table 1, which can be viewed on the journal
website: http://www.jmedgenet.com/supplemental). Analysis
of mutation detection outcomes indicated that, as expected,
family history was a strong indicator of subsequent PHF6
mutation detection, with mutations identified in three of the
five referred familial cases. Skewed X-inactivation in carrier
females was another attribute that indicated increased
likelihood of PHF6 mutation detection, with PHF6 mutations
being carried by three of the five mothers with skewed X-
inactivation. The single clinically diagnosed BFLS female in
whom we identified a PHF6 mutation also showed a skewed
pattern of X-inactivation. A detailed flow chart of the results
of PHF6 screening is shown in fig 1.
Based on the analysis of the initial BFLS families2 we
expected to see concordance between BFLS carrier status and
skewing of X-inactivation. However, as the number of
characterised BFLS cases has increased, the percentage of
obligate carrier females with highly skewed (.90%) X-
inactivation has decreased. Combining the data from this and
our previous study,2 we have now data on carrier females
c.2T→C
p.M1T(×2)
c.134G→A
p.C45Y(×2)
c.296G→T
p.C99F
c.686A→G
p.H229R
c.700A→G
p.K234E0
c.769A→G
p.R257G(×2) Missense
PHDPHD
c.940A→G
p.I314V
‡
‡
†
Nonsensec.1024C→Tp.R342X(×3)
c.22A→T
p.K8X
In/Delc.999_1001delTGAp.D333del
c.27_28insA
p.G10fxX21
Splice siteIVS2-8A→Gp.M46fs
Figure 3 Schematic representation of the PHF6 gene with all mutations identified to date that cause the Bo¨rjeson-Forssman-Lehmann syndrome (BFLS).
Mutations identified in this study (c.2TRC, case 2; c.940ARG, case 1; and c.27_28insA, case 3). Mutation reported by Baumstark et al.10
`Mutations recently published by Vallee et al.11 Unmarked mutations are those previously reported by our group.2 Respective parts of the PHF6 gene
open reading frame coding for nuclear localisation sequences are shown in white and those coding for PHD domains indicated. Four mutations are
recurrent, with p.M1T, p.C45Y and p.R257G each found in two unrelated BFLS families, and p.R342X found in three unrelated BFLS families.
Mutation screening in BFLS 241
www.jmedgenet.com
 on 18 September 2008 jmg.bmj.comDownloaded from 
from 13 unrelated BFLS families. Of these, in three families
the carrier females show random X-inactivation and in a
further three the carrier females show approximately 70%
skewing.2 3 However, carriers in the seven remaining families
show .90% skewed X-inactivation as tested on blood
leucocyte DNA. Taken together, in about 50% of BFLS
families obligate carriers show highly (.90%) skewed X-
inactivation. There does not seem to be a correlation between
the X-inactivation and the type or location of the PHF6
mutation. While in three families with the c.1204CRT
(p.R342X) mutation we see occasionally skewed (.70%),
but more frequently highly skewed (.90%), X-inactivation in
blood of obligate carriers, 2 3 for the c.2TRC (p.M1T)
mutation one obligate carrier is 100% skewed and one shows
random X-inactivation (2 and case 2 in this study).
It must be recognised that although knowledge of X-
inactivation skewing in the mother of the proband, together
with familial occurrence of the BFLS phenotype, is the best
predictor of the detection of a PHF6 mutation, some PHF6
mutations (including de novo mutations) may be missed if
screening is based solely on these criteria. There also remains
the question of the genetic cause in patients with clinically
diagnosed BFLS for whom we have not detected a PHF6
mutation. Underlying genetic heterogeneity (well known for
XLMR disorders) provide one explanation. However, no BFLS
families suggesting this have been reported. Another, more
likely explanation is that the clinical features that raise the
possibility of a BFLS diagnosis are so protean that over-
diagnosis and overlap with Prader-Willi, Wilson-Turner,
Cohen, and Klinefelter syndromes may be common.4
Alternatively, individuals diagnosed with BFLS and tested
negative for PHF6 mutations in the coding region could
harbour mutations not detected by our screening strategy,
such as changes in short or long range regulatory elements,
copy number imbalances, or other rearrangements. Our
current and previous2 gene resequencing analyses of controls
and patients have failed to detect any single nucleotide
variation within the coding region of the PHF6 gene, allowing
us to rule out potential ‘‘splicing spoilers’’ as causative of
BFLS.12
The PHF6 mutations identified thus far are not clustered
within a particular domain, for instance within the PHD-like
zinc finger domains (in fact only one mutation occurs in this
region), nor are they concentrated in any other region of the
protein. The mutations occur along the length of PHF6, and
include missense, nonsense, splice site, deletion, and inser-
tion mutations (fig 3). There is no clear link between
mutation type or location, and the severity of the disease.4
There is one potential mutational hot spot in exon 10,
c.1024CRT, which has been found in three cases (of the 17
known) carrying a PHF6 mutation. The nucleotide C at
position c.1024 is part of a CpG dinucleotide, known to be
often mutated in humans.13
The identification of a female BFLS patient with a PHF6
mutation (case 3) is novel. Unlike many female PHF6
mutation carriers studied so far, she is affected. Varying
expression of clinical features in female carriers had been
reported4 14 and as such this case may represent an extreme.
A likely explanation of such a varying heterozygous expres-
sion may lie in differences in X-inactivation skewing between
tissues (for example, brain versus blood), or a probable non-
cell-autonomous effect of the PHF6 mutation harbouring
cells on those with normal PHF6, similar to the observations
made in Rett syndrome.15 16 The identification of additional
female BFLS cases or the generation of a suitable animal
model will help address this important issue.
In conclusion, we have screened a total of 25 unrelated
individuals with suggested clinical diagnosis of BFLS (24
males and one female) and detected five PHF6 mutations,
two of which have not been identified previously (case 1 and
case 3, fig 2). We assessed the X-inactivation status of the
mothers of 19 of the clinically diagnosed BFLS patients. We
saw skewed (>70%) X-inactivation in five of these cases,
with three PHF6 mutations subsequently detected (two
p.R342X and one p.I314V (case 1)). We identified a further
PHF6 mutation in a family where the obligate carrier mother
did not show a skewed pattern of X-inactivation (p.M1T
(case 2)). The fifth mutation was identified in a female BFLS
patient (p.G10fsX21; case 3, fig 2) and was identified as a de
novo mutation arising on the paternal chromosome. Before
the ascertainment of case 3, we had identified carrier females
(ranging in phenotype from asymptomatic to mildly affected)
only through an affected male relative. Case 3 was the only
referred female BFLS patient. Clinically diagnosed female
BFLS patients have previously been reported,17–19 but never
with subsequent genetic confirmation of the diagnosis. Based
on this finding and the published reports, mutation screening
of the PHF6 gene in clinically diagnosed BFLS female patients
should be considered, particularly if they show a skewed
pattern of X-inactivation.
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CORRECTION
doi: 10.1136/jmg.2005.031369corr1
I
n the Original article titled,
Oculocerebrocutaneous syndrome: the
brain malformation defines a core pheno-
type (J Med Genet 2005;42:913-921) the
supplementary figures were missing from
the paper. The supplementary figures are
available on the JMG website at http://
www.jmedgenet.com/supplemental.
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